Galmed Pharmaceuticals Ltd. GLMD (NASDAQ:GLMD) on 18 march announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters’ option to purchase additional ordinary shares to cover over-allotments. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares after opening at $11.79 moved to $11.79 on last trade day and at the end of the day closed at $11.10. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 1130.54. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) showed a negative weekly performance of -24.54%.
Ignyta, Inc. (NASDAQ:RXDX), an oncology precision medicine biotechnology company, announced the underwriters’ full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company’s common stock, at a price to the public of $9.15 per share. Ignyta Inc. (NASDAQ:RXDX) shares fell -3.58% in last trading session and ended the day on $8.63.
Akebia Therapeutics (NASDAQ:AKBA) Insider A/S Novo acquired 182,590 shares of the stock on the open market in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $17.00 per share, with a total value of $3,104,030.00. Following the purchase, the insider now directly owns 1,516,387 shares in the company, valued at approximately $25,778,579. Akebia Therapeutics Inc. (NASDAQ:AKBA) shares moved down -5.20% in last trading session and was closed at $18.96, while trading in range of $18.75 – $20.00. Akebia Therapeutics Inc. (NASDAQ:AKBA) year to date (YTD) performance is -28.96%.
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have not generated any revenue from commercial product sales since we commenced operations. In the future, if birinapant is approved for commercial sale, Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) may generate revenue from product sales, or alternatively, company may choose to select a collaborator or licensee to commercialize birinapant. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) weekly performance is -19.95%. On last trading day company shares ended up $6.18. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) distance from 50-day simple moving average (SMA50) is -32.31%. Analysts mean target price for the company is $15.50.